Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug (JMT101) plus Osimertinib vs Chemo in EGFR Exon 20ins NSCLC
NCT06380348Phase 3Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of becotatug in non-small cell lung cancer (NSCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
becotatug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06380348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06380348.